Tsumura & Co
TSE:4540
Tsumura & Co
Cash Equivalents
Tsumura & Co
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tsumura & Co
TSE:4540
|
Cash Equivalents
¥83.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash Equivalents
¥494.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash Equivalents
¥682.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cash Equivalents
¥426.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash Equivalents
¥393.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cash Equivalents
¥179.9B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
Tsumura & Co
Glance View
Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.
See Also
What is Tsumura & Co's Cash Equivalents?
Cash Equivalents
83.1B
JPY
Based on the financial report for Dec 31, 2024, Tsumura & Co's Cash Equivalents amounts to 83.1B JPY.
What is Tsumura & Co's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
15%
Over the last year, the Cash Equivalents growth was 3%. The average annual Cash Equivalents growth rates for Tsumura & Co have been 7% over the past three years , 6% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet